Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer

Trial Identifier: D931CC00001
Sponsor: AstraZeneca
Start Date: November 2022
Primary Completion Date: November 2024
Study Completion Date: December 2026
Condition: Breast Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AT Rankweil, AT, 6830
AT Salzburg, AT, 5020
AU Melbourne, AU, 3000
BE Brussel, BE, 1200
BE Liège, BE, 4000
DE Augsburg, BY, DE, 86156
DE Essen, DE, 45130
DE Hamburg, DE, 20246
DE Hannover, DE, 30625
DE Heidelberg, DE, 69120
DE Köln, DE, 50931
DE Munchen, DE, 81377
ES A Coruña, ES, 15006
ES Barcelona, ES, 08036
ES Barcelona, ES, 8035
ES Caceres, ES, 10003
ES Hospitalet deLlobregat, ES, 08907
ES Lérida, ES, 25198
ES Madrid, ES, 28041
ES Málaga, ES, 29010
ES Sevilla, ES, 41009
ES Sevilla, ES, 41013
ES Valencia, ES, 46010
GB Nottingham, GB, NG5 1PB
IL Jerusalem, IL, 91120
IL Kfar Saba, IL, 44218
IL Ramat Gan, IL, 5262000
IL Rehovot, IL, 76100
IT Bologna, IT, 40138
IT Meldola, IT, 47014
IT MODENA, IT, 41124
IT Roma, IT, 00168
US, CO Greeley, CO, US, 80631
US, CO Loveland, CO, US, 80537
US, MA Boston, MA, US, 02215
US, OR Portland, OR, US, 97239
US, PA Philadelphia, PA, US, 19104